000168190 001__ 168190
000168190 005__ 20240229133600.0
000168190 0247_ $$2doi$$a10.1038/s41416-021-01347-4
000168190 0247_ $$2pmid$$apmid:33772152
000168190 0247_ $$2ISSN$$a0007-0920
000168190 0247_ $$2ISSN$$a1532-1827
000168190 0247_ $$2altmetric$$aaltmetric:102797658
000168190 037__ $$aDKFZ-2021-00730
000168190 041__ $$aEnglish
000168190 082__ $$a610
000168190 1001_ $$aAmadou, Amina$$b0
000168190 245__ $$aPrevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
000168190 260__ $$aEdinburgh$$bNature Publ. Group$$c2021
000168190 3367_ $$2DRIVER$$aarticle
000168190 3367_ $$2DataCite$$aOutput Types/Journal article
000168190 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625056785_11425
000168190 3367_ $$2BibTeX$$aARTICLE
000168190 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168190 3367_ $$00$$2EndNote$$aJournal Article
000168190 500__ $$a2021 May;124(11):1882-1890
000168190 520__ $$aWe investigated whether associations between prevalent diabetes and cancer risk are pertinent to older adults and whether associations differ across subgroups of age, body weight status or levels of physical activity.We harmonised data from seven prospective cohort studies of older individuals in Europe and the United States participating in the CHANCES consortium. Cox proportional hazard regression was used to estimate the associations of prevalent diabetes with cancer risk (all cancers combined, and for colorectum, prostate and breast). We calculated summary risk estimates across cohorts using pooled analysis and random-effects meta-analysis.A total of 667,916 individuals were included with an overall median (P25-P75) age at recruitment of 62.3 (57-67) years. During a median follow-up time of 10.5 years, 114,404 total cancer cases were ascertained. Diabetes was not associated with the risk of all cancers combined (hazard ratio (HR) = 0.94; 95% confidence interval (CI): 0.86-1.04; I2 = 63.3%). Diabetes was positively associated with colorectal cancer risk in men (HR = 1.17; 95% CI: 1.08-1.26; I2 = 0%) and a similar HR in women (1.13; 95% CI: 0.82-1.56; I2 = 46%), but with a confidence interval including the null. Diabetes was inversely associated with prostate cancer risk (HR = 0.81; 95% CI: 0.77-0.85; I2 = 0%), but not with postmenopausal breast cancer (HR = 0.96; 95% CI: 0.89-1.03; I2 = 0%). In exploratory subgroup analyses, diabetes was inversely associated with prostate cancer risk only in men with overweight or obesity.Prevalent diabetes was positively associated with colorectal cancer risk and inversely associated with prostate cancer risk in older Europeans and Americans.
000168190 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000168190 588__ $$aDataset connected to CrossRef, PubMed,
000168190 7001_ $$00000-0001-8648-4998$$aFreisling, Heinz$$b1
000168190 7001_ $$aJenab, Mazda$$b2
000168190 7001_ $$aTsilidis, Konstantinos K$$b3
000168190 7001_ $$aTrichopoulou, Antonia$$b4
000168190 7001_ $$aBoffetta, Paolo$$b5
000168190 7001_ $$aVan Guelpen, Bethany$$b6
000168190 7001_ $$aMokoroa, Olatz$$b7
000168190 7001_ $$aWilsgaard, Tom$$b8
000168190 7001_ $$aKee, Frank$$b9
000168190 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b10$$udkfz
000168190 7001_ $$aOrdóñez-Mena, José M$$b11
000168190 7001_ $$aMännistö, Satu$$b12
000168190 7001_ $$aSöderberg, Stefan$$b13
000168190 7001_ $$aVermeulen, Roel C H$$b14
000168190 7001_ $$aQuirós, J Ramón$$b15
000168190 7001_ $$aLiao, Linda M$$b16
000168190 7001_ $$aSinha, Rashmi$$b17
000168190 7001_ $$00000-0003-2165-1411$$aKuulasmaa, Kari$$b18
000168190 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b19$$udkfz
000168190 7001_ $$aRomieu, Isabelle$$b20
000168190 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-021-01347-4$$n11$$p1882-1890$$tBritish journal of cancer$$v124$$x1532-1827$$y2021
000168190 909CO $$ooai:inrepo02.dkfz.de:168190$$pVDB
000168190 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000168190 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000168190 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000168190 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000168190 9141_ $$y2021
000168190 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2019$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000168190 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2019$$d2021-01-28
000168190 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000168190 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000168190 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000168190 980__ $$ajournal
000168190 980__ $$aVDB
000168190 980__ $$aI:(DE-He78)C070-20160331
000168190 980__ $$aI:(DE-He78)C120-20160331
000168190 980__ $$aI:(DE-He78)HD01-20160331
000168190 980__ $$aUNRESTRICTED